Sign in with Google
USPI Labeling
Join our community on Telegram!
Join the biggest community of Pharma students and professionals.
What Is USPI Labeling?
USPI Labeling means United States Prescribing Information. It is the official FDA-approved prescribing document for a prescription drug marketed in the United States. This document provides scientifically validated, regulatory-controlled information that healthcare professionals use for safe and effective prescribing.
USPI is regulated by the U.S. Food and Drug Administration under 21 CFR 201.56 and 21 CFR 201.57. The format followed is known as the Physician Labeling Rule format. Every product approved through NDA or ANDA must have an approved USPI.
Regulatory Foundation
| Parameter | Details |
|---|---|
| Governing Authority | U.S. Food and Drug Administration |
| Legal Basis | 21 CFR 201.56 and 201.57 |
| Applicable Applications | NDA, ANDA, BLA |
| Format Name | Physician Labeling Rule (PLR) |
| Audience | Physicians, pharmacists, healthcare professionals |
Purpose of USPI
USPI serves as the primary scientific communication between the sponsor and healthcare professionals. It defines approved indications, dosing instructions, contraindications, safety risks, pharmacology data, and clinical trial evidence. It is also a legal document. Any promotional claim made by a pharmaceutical company must be consistent with the approved USPI. During inspections and legal disputes, the USPI is considered an authoritative reference.
Overall Structure of USPI
USPI is divided into three major components.
| Major Section | Description |
|---|---|
| Highlights of Prescribing Information | Concise summary of critical prescribing details |
| Full Prescribing Information | Detailed scientific and regulatory information |
| Patient Counseling Information | Guidance for healthcare professionals to educate patients |
Highlights of Prescribing Information
This section appears at the beginning of the document and provides a quick reference summary. It includes boxed warning if applicable, recent major changes, indications and usage, dosage and administration, dosage forms and strengths, contraindications, warnings and precautions, adverse reactions, drug interactions, use in specific populations, and the revision date.
Full Prescribing Information
This section contains detailed content organized in numbered headings from 1 to 17. Each section has a fixed regulatory title and sequence that must be strictly followed.
| Section Number | Title |
|---|---|
| 1 | Indications and Usage |
| 2 | Dosage and Administration |
| 3 | Dosage Forms and Strengths |
| 4 | Contraindications |
| 5 | Warnings and Precautions |
| 6 | Adverse Reactions |
| 7 | Drug Interactions |
| 8 | Use in Specific Populations |
| 9 | Drug Abuse and Dependence |
| 10 | Overdosage |
| 11 | Description |
| 12 | Clinical Pharmacology |
| 13 | Nonclinical Toxicology |
| 14 | Clinical Studies |
| 15 | References |
| 16 | How Supplied/Storage and Handling |
| 17 | Patient Counseling Information |
Each section has a defined regulatory expectation. For example, Section 12 Clinical Pharmacology must include mechanism of action, pharmacodynamics, and pharmacokinetics. Section 14 Clinical Studies must summarize pivotal trials that support approval. Section 6 Adverse Reactions must present safety data derived from clinical trials and post-marketing experience.
Patient Counseling Information
This final portion provides key risk communication points that healthcare professionals should discuss with patients. It may include risk of serious adverse reactions, instructions for administration, pregnancy warnings, and safe storage advice. A Medication Guide may also be required if mandated by FDA for serious safety concerns.
USPI in NDA versus ANDA
For an NDA, the innovator company prepares the original labeling based on clinical and nonclinical data. For an ANDA, the generic company must match the Reference Listed Drug labeling except for permissible differences such as manufacturer name, inactive ingredients, or certain patent-related statements.
Lifecycle Management of USPI
Labeling is not static. It is continuously updated when new safety or efficacy data becomes available. Updates may be submitted as labeling supplements depending on the nature of the change.
| Type of Change | Regulatory Pathway |
|---|---|
| Major safety change | Prior Approval Supplement |
| Certain safety updates | Changes Being Effected (CBE-0 or CBE-30) |
| Minor editorial changes | Annual Report |
Importance in Regulatory Affairs and Medical Writing
USPI drafting is a critical responsibility in regulatory affairs. Medical writers prepare and update labeling based on clinical study reports, integrated summaries, and FDA guidance. Regulatory professionals ensure alignment between labeling, clinical data, and promotional materials. Proper labeling compliance is evaluated during FDA review, inspections, and post-marketing surveillance.
